Related Experiment Videos
Transurethral ethanol injection therapy for prostatic hyperplasia: 3-year results
Nobuyuki Goya1, Nobuo Ishikawa, Fumio Ito
1Department of Urology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan. goya@kc.twmu.ac.jp
The Journal of Urology
|August 18, 2004
Summary
Transurethral ethanol injection therapy (EIP) for benign prostatic hyperplasia offers medium-term symptom relief and improved urine flow with minimal complications. Most patients avoided further treatment three years post-procedure.
Area of Science:
- Urology
- Minimally Invasive Procedures
- Medical Device Technology
Background:
- Benign prostatic hyperplasia (BPH) is a common condition in aging men.
- Current BPH treatments have varying efficacy and risk profiles.
- Transurethral ethanol injection therapy (EIP) is an emerging minimally invasive option.
Purpose of the Study:
- To evaluate the medium-term (3-year) efficacy and safety of transurethral ethanol injection therapy (EIP) for benign prostatic hyperplasia (BPH).
Main Methods:
- 34 male patients with BPH underwent transurethral EIP under anesthesia.
- Ethanol was injected endoscopically; a urethral catheter was used postoperatively.
- Patients were followed for a median of 4.3 years, with assessments of symptom scores, quality of life, and urine flow.
Main Results:
- Significant improvements were observed in International Prostate Symptom Score (IPSS), quality of life, peak urine flow rate, and residual urine volume after 3 years.
- Mean prostate volume initially decreased but showed a slight increase by year 3.
- No major complications were reported, and 59% of patients did not require further treatment by 3 years.
Conclusions:
- Transurethral EIP is a safe procedure with minimal complications for BPH.
- EIP provides sustained improvement in BPH symptoms and urinary flow for up to 3 years.
- A significant proportion of patients remain free from additional treatments post-EIP.